Structural and clinical impact of anti-allergy agents: An overview

• Published in: Bioorganic chemistry Vol. 94; p. 103351
• Main Authors: Kapoor, Yagyesh, Kumar, Kapil
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2020
• Subjects: 5-Lipoxygenase inhibitors; Allergic disorders; Allergic inflammation; Anti-Allergic Agents - chemistry; Anti-Allergic Agents - therapeutic use; Anti-allergic drugs; Asthma; Dermatitis; FLAP inhibitors; Glucocorticoids; Histamine H1 antagonists; Humans; Hypersensitivity - drug therapy; IgE inhibitor; IL-5 inhibitors; Immunoglobulin E; Leukotriene antagonists; Mediator-release inhibitors; Monoclonal antibodies; Rhinitis; Th2 cytokine inhibitors; Thromboxane A2 inhibitors; Allergic inflammation; Rhinitis; Glucocorticoids; Immunoglobulin E; IL-5 inhibitors; FLAP inhibitors; Dermatitis; Allergic disorders; Anti-allergic drugs; Asthma; Thromboxane A2 inhibitors; Mediator-release inhibitors; Leukotriene antagonists; Th2 cytokine inhibitors; IgE inhibitor; Histamine H1 antagonists; 5-Lipoxygenase inhibitors; Monoclonal antibodies; Histamine H antagonists; Th cytokine inhibitors; Thromboxane A inhibitors
• ISSN: 0045-2068; 1090-2120; 1090-2120
• DOI: 10.1016/j.bioorg.2019.103351

[Display omitted] Allergic disorders are markedly rising in industrialized countries. The identification of compounds that trigger the immunoglobulin E (IgE)-dependent allergic reaction remain the means to improve the quality of life by limiting patient’s exposure to critical allergens. Information concerning the treatment and onset of allergic disorders including atopic dermatitis, allergic rhinitis, and bronchial asthma has been provided by the research over the past decade. Recent studies also indicated that allergic inflammation is associated closely with their exacerbation and progression and indeed is the basic pathophysiology of allergic diseases. As a result of immunological and molecular biological studies our understanding of the mechanism of allergic inflammation with regard to therapeutic agents has improved. While much effort has been paid to developing a new anti-allergic agent, the allergic disease has yet to be completely conquered. The more extensive research will allow the development of new therapeutics to combat allergic diseases. Currently, with respect to mechanism of action anti-allergy drugs are classified into five types including histamine H1 antagonists, leukotriene antagonists, Th2 cytokine inhibitors, thromboxane A2 inhibitors and mediator-release inhibitors. The use of two or more anti-allergy agents together is not acknowledged at present, but this will be the subject of research in the future because with different mechanisms of action anti-allergy agents used at the same time will theoretically increase their effects. This review article focuses on anti-allergy agents highlighting their applications, clinical trials and recent advancement on drugs.